<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">GAUCHEZ, ANNE-SOPHIE</style></author><author><style face="normal" font="default" size="100%">COLONNA, MARC</style></author><author><style face="normal" font="default" size="100%">BRAND, FRANÇOIS-XAVIER</style></author><author><style face="normal" font="default" size="100%">RAVANEL, NADIA</style></author><author><style face="normal" font="default" size="100%">PASQUIER, DOMINIQUE</style></author><author><style face="normal" font="default" size="100%">PAYAN, RAOUL</style></author><author><style face="normal" font="default" size="100%">MOUSSEAU, MIREILLE</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Kinetics of HER2/neu ECD in 45 Patients Treated with Trastuzumab (Herceptin®) between January 2001 and June 2005 at the Grenoble University Hospital</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1703-1707</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><issue><style face="normal" font="default" size="100%">5</style></issue><abstract><style  face="normal" font="default" size="100%">The aim of this study was to evaluate the utility of HER2/neu ECD concentration as a marker of the efficacity of clinical response to Herceptin®. Patients and Methods: Iterative measurements of HER2/neu ECD (ELISA c-erbB2/c-neu Rapid Format Elisa kit QIA10™ Calbiochem®) concentrations in 45 patients treated with Herceptin® between January 2001 and June 2005 at the Grenoble University Hospital. Results: Changes in HER2/neu ECD concentrations were observed in 21 patients (47%). The baseline concentration was the concentration of circulating HER2/neu ECD before treatment with Herceptin®. In 15 patients, the mean baseline concentration was 52 ng mL-1 (extreme values 13-170), which normalized no later than at the time of the 3rd administration of Herceptin®. Nine patients (60%) were still alive 5 years later (p&lt;0.05). For 6 patients, the mean baseline concentration was 800 ng mL-1 (extreme values 140-2000) which persisted and even increased during Herceptin® therapy; fewer than 25% were alive 30 months later (p&lt;0.05). In the case of the 24 patients whose HER2/neu ECD concentration remained &lt;5 ng mL-1, survival time was intermediate. Conclusion: The study confirmed the utility of HER2/neu ECD in predicting therapeutic response. However, as in the case of other circulating tumor markers, it is only useful when there is a variation in concentration. This marker should now be evaluated in multi-center studies covering a large number of homogeneous subjects.</style></abstract></record></records></xml>